Latest news with #BrianShields
Yahoo
2 days ago
- Health
- Yahoo
Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK®
Effective September 15, CPT 31242 is no longer considered experimental, clearing an important barrier for ENT physicians treating chronic rhinitis. GALWAY, Ireland, June 30, 2025 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that Cigna Healthcare will provide coverage for NEUROMARK treatment of the posterior nasal nerve by removing CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15th, 2025. This policy update is an important step in improving patient access to innovative treatment options for chronic rhinitis and reflects growing payer recognition of the procedure's therapeutic value. This update removes a key barrier that previously limited the ability for ENT physicians to treat Cigna patients using posterior nasal nerve ablation. "This is a significant moment for ENT providers and patients alike," said Brian Shields, CEO of Neurent Medical. "Cigna's reclassification of CPT 31242 reinforces the evolving understanding of chronic rhinitis and the role of targeted, minimally invasive interventions like NEUROMARK in managing the condition. We are committed to continue building on our large evidence base and working closely with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to support adoption across the US healthcare system" The NEUROMARK System delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt the parasympathetic nerve signals, addressing key symptoms of Chronic Rhinitis such as persistent nasal congestion and rhinorrhea (runny nose). "Chronic rhinitis can significantly affect an individual's wellbeing and patients need access to all available, medically sound solutions" said Dr. Peter Manes, Associate Professor at Yale School of Medicine. "This policy update is significant and helps otolaryngologists offer a modern, evidence-supported treatment with fewer administrative hurdles. The large and growing evidence base makes it more difficult for patients to be denied access to such technologies." Key Points for Providers: CPT 31242 is no longer classified as investigational by Cigna Precertification is not required under the updated policy (always confirm benefits per individual plan) The policy supports more streamlined access to NEUROMARK for eligible patients To view Cigna's updated medical policy, visit:CIGNA Policy LINK For more information about NEUROMARK, visit or contact your local Neurent Medical Sales Representative. About Neurent Medical Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology, with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visit PAM225r01 View original content to download multimedia: SOURCE Neurent Medical
Irish Examiner
17-06-2025
- Business
- Irish Examiner
Medtech firm Neurent to create 125 jobs in Galway hub
Healthcare company Neurent Medical is to create 125 jobs in Galway at its new manufacturing facility at Westlink Commercial Park in Oranmore. The company is a leader in ear, nose, and throat (ENT) healthcare solutions and will create positions in engineering, quality control, operations, supply chain, and sales and marketing at the new facility, over the next three years. The Galway headquarters will serve as a hub for production of the company's Neuromark treatment option to treat chronic rhinitis. 'We're proud to scale our operations in Galway, where the medtech ecosystem continues to thrive. Our new Westlink facility gives us the manufacturing capacity to meet growing demand for Neuromark, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland," said Neurent Medical chief Brian Shields. Neurent's Neuromark system recently received US FDA 510(k) clearance, which paves the way for broader commercialisation of its product in the US. "Neurent Medical has experienced impressive growth in a short period of time beginning its journey through the BioInnovate Ireland Programme here in Galway with further support awarded through EI's Commercialisation fund programme and through the Disruptive Technologies Innovation Fund administered by Enterprise Ireland for the development of the NEUROMARK technology,' said incoming Enterprise Ireland chief Jenny Melia.
RTÉ News
17-06-2025
- Business
- RTÉ News
Neurent Medical to create 125 jobs in Galway
Healthcare company Neurent Medical is to create 125 new highly skilled jobs in Galway over the next three years. The announcement comes as the company officially opened its new state-of-the-art manufacturing facility at Westlink Commercial Park in Oranmore. The new facility will serve as the central hub for the production of the company's Neuromark system, a treatment option designed to target the underlying drivers of chronic Rhinitis. The new Galway jobs will range across key functions in engineering, quality control, operations, supply chain management, and sales and marketing. Originating from the Enterprise Ireland-supported BioInnovate Ireland Programme, Neurent Medical has grown from concept to commercialisation within a decade, emerging as one of the country's MedTech success stories. Since its inception, it said it has leveraged Galway's world-class innovation ecosystem to scale its team, secure FDA regulatory clearances and attract top international clinical collaborators. Brian Shields, CEO of Neurent Medical, said the company was proud to scale its operations in Galway, where the MedTech ecosystem continues to thrive. "Our new Westlink facility gives us the manufacturing capacity to meet growing demand for Neuromark, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland," he said. "As an Irish-founded company, we're excited to manufacture our product locally with the exceptional skills available and deliver Irish-engineered MedTech innovation to the world," he added. Jenny Melia, Executive Director and incoming CEO at Enterprise Ireland, said today's announcement of new jobs based here in Oranmore shows that Ireland is leading in research and development within the medical device space. "Neurent Medical has experienced impressive growth in a short period of time beginning its journey through the BioInnovate Ireland Programme here in Galway with further support awarded through EI's Commercialisation fund programme and through the Disruptive Technologies Innovation Fund administered by Enterprise Ireland for the development of the Neuromark technology," she said. "Supporting Irish companies with the ambition to scale globally is a key priority for Enterprise Ireland and we will continue to work closely with Brian and the team at Neurent Medical to optimise their full international growth potential, creating and sustaining jobs here in the Galway region," she added. Hildegarde Naughton, Minister of State at the Department of Children, Disability and Equality, noted that Galway is home to eight of the world's top 10 MedTech companies. "It is also highly notable that this is an Irish company, supported by Enterprise Ireland, and selling into the US market. I have no doubt, given their impressive growth to date, that this will be but one of many major achievements for the company," she added.
Irish Times
17-06-2025
- Business
- Irish Times
Neurent Medical to create 125 jobs at new manufacturing facility in Galway
Galway medtech company Neurent Medical is to create 125 jobs at its new manufacturing facility. The jobs, which will be in engineering, quality control, operations, supply chain, and sales and marketing, will be created by the end of 2028. Neurent Medical has developed a minimally invasive device that helps deal with the inflammatory response that leads to rhinitis, or chronic runny nose. It will be manufactured at the new facility, which was officially opened on Tuesday at Westlink Commercial Park in Oranmore, Co Galway. READ MORE The move follows the recent FDA clearance for the next-generation Neuromark system, which opens the way for further commercialisation in the US. 'We're proud to scale our operations in Galway, where the MedTech ecosystem continues to thrive. Our new Westlink facility gives us the manufacturing capacity to meet growing demand for Neuromark, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland,' said Brian Shields, CEO of Neurent Medical. 'As an Irish-founded company, we're excited to manufacture our product locally with the exceptional skills available and deliver Irish-engineered MedTech innovation to the world.' It also expands the growing medtech ecosystem in Galway. Neurent Medical has its roots in the Enterprise Ireland-supported BioInnovate Ireland Programme, founded by Mr Shields and chief technology officer David Townley as a spin-out, and has grown from concept to commercialisation within a decade. 'Today's announcement of new jobs based here in Oranmore shows that Ireland is leading in research and development within the medical device space,' said chief executive designate of Enterprise Ireland Jenny Melia. 'Supporting Irish companies with the ambition to scale globally is a key priority for Enterprise Ireland and we will continue to work closely with Brian and the team at Neurent Medical to optimise their full international growth potential, creating and sustaining jobs here in the Galway region.' The opening was attended by Minister of State at the Department of Children, Disability and Equalit yHildegarde Naughton. 'Galway is known as a major player in Medical Technology, being home to eight of the world's top 10 MedTech companies,' she said. 'Today's announcement is further evidence of that and, as a native myself, I am particularly proud to see 125 new highly skilled jobs being created by a company based in Oranmore. It is also highly notable that this is an Irish company, supported by Enterprise Ireland, and selling into the US market.'
Yahoo
12-06-2025
- Health
- Yahoo
FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment
The US Food and Drug Administration (FDA) has granted 510(k) clearance to Neurent Medical's NEUROMARK system for the treatment of individuals with chronic rhinitis. Comprising a single-use, handheld bipolar radiofrequency (RF) device and a reusable console with a graphical user interface, the system is designed to conform to the anatomy of the patient and target nerve-rich regions in the nasal cavity. Its bioimpedance monitoring technology adjusts energy delivery based on the changes in tissue conductivity. This method makes sure treatment is precise by continuously evaluating the conditions of the tissue and adjusting energy flow, thereby increasing therapeutic outcomes. According to the company, the system's real-time feedback and smart algorithmic control are crucial for directing the proper placement of the electrode and ensuring treatment delivery success. Its atraumatic leaflets and flexible haft will aid physicians in accessing challenging nasal cavity areas and increase the treatment coverage, along with the posterior areas of the lateral nasal wall. The system claims to operate by delivering impedance-controlled, low-power RF energy to disrupt parasympathetic nerve signals. This addresses the primary symptoms of chronic rhinitis, which include rhinorrhoea (runny nose) and persistent congestion in the nasal area. With the FDA clearance, the system is set for broader availability in the US market. The Ireland-based company focuses on chronic inflammatory sino-nasal disease treatments. Neurent Medical CEO Brian Shields said: 'We have just completed a highly successful commercial validation phase, positioning the NEUROMARK system at the forefront of chronic rhinitis care. 'During this phase, we collaborated with leading General ENT [ear, nose, and throat] and rhinology specialists across both private practice and academic settings. Their insights were instrumental in shaping this next-generation system. I am incredibly proud of how their feedback translated into meaningful technological improvements.' "FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
